View Older Stories View More Recent Stories

Feb 14, 2022 05:31PM Form SC 13G/A ChemoCentryx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 05:15PM Form SC 13G/A ImmunoGen, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 05:15PM Form SC 13G/A Atea Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 05:14PM Form 13F-HR RA CAPITAL MANAGEMENT, For: Dec 31

Feb 14, 2022 04:59PM Form SC 13G/A Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:59PM Form SC 13G/A Seres Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:46PM Form SC 13G/A CONCERT PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:46PM Form SC 13G/A ZOGENIX, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:35PM Form SC 13G/A 5:01 Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:35PM Form SC 13G/A Silverback Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:35PM Form SC 13G/A scPharmaceuticals Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:35PM Form SC 13G/A Cyteir Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:35PM Form SC 13G/A Xilio Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:35PM Form SC 13G/A Viridian Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:26PM Form SC 13G/A OTONOMY, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:26PM Form SC 13G Edgewise Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:26PM Form SC 13G/A Larimar Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:26PM Form SC 13G/A KalVista Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:26PM Form SC 13G/A MACROGENICS INC Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:26PM Form SC 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:25PM Form SC 13G/A Tango Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:25PM Form SC 13G/A BCLS Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:21PM Form SC 13G/A Verona Pharma plc Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:21PM Form SC 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:21PM Form SC 13G/A Orchard Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:21PM Form SC 13G/A Pyxis Oncology, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:21PM Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:21PM Form SC 13G/A PhaseBio Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:21PM Form SC 13G/A Travere Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A Ascendis Pharma A/S Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A Nautilus Biotechnology, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A Akouos, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A NOVAVAX INC Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A GERON CORP Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A Milestone Pharmaceutical Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A Olema Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A Dyne Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A CytomX Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A Astria Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 14, 2022 04:20PM Form SC 13G/A Frazier Lifesciences Filed by: RA CAPITAL MANAGEMENT, L.P.

Feb 10, 2022 09:00AM Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines

Feb 10, 2022 07:30AM Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multip

Feb 9, 2022 08:00AM AavantiBio Announces Formation of Scientific Advisory Board

Feb 9, 2022 07:00AM Ventus Therapeutics Closes $140 Million Series C Financing

Feb 4, 2022 08:00AM Hemab Therapeutics Announces First Drug Candidate: HMB-001, a Novel Bispecific Antibody with Potential for Treatment of Rare Bleeding Disorders

Jan 25, 2022 08:00AM Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

Jan 19, 2022 08:00AM PepGen Appoints Laurie Keating as Chair of Board of Directors

Jan 12, 2022 06:45AM TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

Jan 12, 2022 06:45AM TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

Jan 10, 2022 05:01PM Form SC 13G PARDES BIOSCIENCES, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.

View More Recent Stories View Older Stories